샘플 요청 목록

 카트 문의
시장보고서
상품코드
1773919

세계의 타겟 DNA RNA 시퀀싱 시장

Targeted DNA RNA Sequencing
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 568 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

타겟 DNA RNA 시퀀싱 세계 시장은 2030년까지 314억 달러에 달할 전망

2024년에 117억 달러로 추정되는 타겟 DNA RNA 시퀀싱 세계 시장은 2024년부터 2030년까지 CAGR 17.9%로 성장하여 2030년에는 314억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 NGS는 CAGR 15.8%를 기록하며 분석 기간 종료까지 170억 달러에 달할 것으로 예측됩니다. 기타 제품 부문의 성장률은 분석 기간 동안 CAGR 20.7%로 추정됩니다.

미국 시장은 32억 달러로 추정, 중국은 CAGR 23.2%로 성장 예측

미국의 타겟 DNA RNA 시퀀싱 시장은 2024년에 32억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 69억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 23.2%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 13.5%와 16.0%로 예측됩니다. 유럽에서는 독일이 CAGR 약 14.2%로 성장할 것으로 예측됩니다.

세계의 타겟 DNA RNA 시퀀싱 시장 - 주요 동향과 촉진요인 정리

타겟 DNA RNA 시퀀싱이 전장 유전체 및 전사체 접근법을 능가하는 이유는 무엇인가?

정밀의료와 하이스루풋 유전체학의 시대에, 타겟 DNA RNA 시퀀싱은 전체 유전체 및 전사체 시퀀싱을 대체할 수 있는 실용적이고 효율적인 방법으로 부상하고 있습니다. 이 방법은 관심 있는 특정 유전체 영역이나 전사체의 하위 집합에 집중함으로써 유전적 변이, 발현 프로파일, 분자 바이오마커를 조사할 수 있는 비용 효율적이고 확장 가능하며 임상적으로 적합한 방법을 제공합니다. 방대한 양의 관련 없는 데이터를 생성하고 집중적인 컴퓨팅 리소스를 필요로 하는 전장 염기서열 분석과 달리, 타겟 시퀀싱을 통해 연구자와 임상의는 질병 경로와 관련된 알려진 유전자, 조절 요소, 돌연변이 핫스팟을 식별할 수 있습니다. 예를 들어, 종양학에서 표적화 시퀀싱 패널을 통해 임상의는 보다 빠른 처리 속도와 더 나은 해석 가능성으로 암 관련 유전자 전체에서 실용적인 돌연변이를 식별할 수 있습니다. 감염성 질환 연구에서는 표적 RNA 시퀀싱을 통해 병원체 특이적 전사체를 분석하여 균주 식별 및 약물 내성 프로파일링에 도움을 줄 수 있습니다. 또한, 유전성 질환의 진단, 약리유전체학, 면역 레퍼토리 프로파일링은 정확하고 재현성 있는 결과를 얻기 위해 표적 분석에 대한 의존도가 높아지고 있습니다. 헬스케어 및 생명과학 산업이 임상적으로 실용적이고 시간적 제약이 없는 유전자 데이터를 요구하고 있는 가운데, 표적 시퀀싱 방법은 연구와 임상의 실용성 사이의 간극을 메우고, 과도한 데이터 노이즈의 부담 없이 영향력 있는 생물학적 질문에 답하는 데 필요한 깊이와 특이성을 제공합니다.

기술 혁신을 통해 타겟 시퀀싱의 효율성과 정확성이 어떻게 향상되고 있는가?

시퀀싱 화학, 프로브 설계, 증폭 프로토콜, 바이오인포매틱스의 발전으로 타겟 DNA RNA 시퀀싱의 민감도, 특이성, 처리량이 크게 향상되었습니다. 하이브리드 캡처 및 amplicon 기반 농축과 같은 기술은 더욱 정교해져 저빈도 변이체 및 구조적으로 복잡한 유전체 영역을 정확하게 타겟팅할 수 있게 되었습니다. 적응형 샘플링 기술은 나노포어 시퀀싱 플랫폼에서 실시간 타겟 선택이 가능하여 낭비되는 리드를 줄이고 효율을 향상시키고 있습니다. 멀티플렉스 라이브러리 준비 키트와 자동화에 적합한 워크플로우를 통해 납기를 단축하고 시료 취급 오류를 줄이며, 저투입 키트와 FFPE 지원 키트를 통해 임상 시료 및 열화 시료의 유용성을 확대합니다. 데이터 분석 측면에서는 통합된 바이오인포매틱스 파이프라인과 AI가 탑재된 변이 콜러가 염기서열 분석이 어려운 영역에서도 리드 매핑, 돌연변이 검출, 전사체 정량화의 신뢰성을 높이고 있습니다. 클라우드 기반 플랫폼은 공동 연구, 안전한 데이터 저장, 임상 실험실의 간소화된 보고를 촉진합니다. 또한, 듀얼 DNA/RNA 패널의 개발로 단일 샘플에서 유전체와 트랜스크립톰의 통합 프로파일링이 가능해졌으며, 이는 특히 종양학 및 면역 프로파일링 애플리케이션에 유용합니다. 이러한 기술 혁신은 리드 정확도의 향상, 시퀀서의 고속화, 시약 키트의 가격 인하와 함께 타겟 시퀀싱은 단순한 중점적인 방법이 아닌 정밀 진단 및 번역 연구를 위한 기술적으로 정교하고 광범위하게 적용 가능한 솔루션으로 발전하고 있습니다.

타겟 DNA RNA 시퀀싱은 어디에 적용되고 있으며, 어떤 사용 사례가 생겨나고 있는가?

타겟 DNA RNA 시퀀싱은 임상, 학술 및 산업 분야에서 광범위하게 사용되고 있으며, 응용 분야는 전통적인 유전체 연구의 틀을 크게 벗어나고 있습니다. 임상 종양학에서 표적 시퀀싱 패널은 이제 고형 종양 및 혈액 악성 종양의 일상적인 검사로 자리 잡았으며, 실용적인 돌연변이 식별, 치료 선택 지침, 미세 잔존 질환 모니터링에 도움이 되고 있습니다. 생식 의학 및 희귀 질환 진단에서 표적 분석은 정의된 유전자 세트에서 병원성 변이를 신속하게 스크리닝하여 진단 수율을 향상시키면서 비용과 시간을 단축할 수 있습니다. 감염성 질환 연구에서는 병원체 특이적 RNA 시퀀싱이 새로운 변종, 항균제 내성 마커, 치료제에 대한 전사 반응의 신속한 식별에 활용되고 있습니다. 면역학 및 백신 개발 분야에서는 표적 T 세포 및 B 세포 수용체 염기서열을 활용하여 면역 레퍼토리와 반응 동역학을 연구하고 있습니다. 헬스케어 분야 외에도 농업유전체학 연구자들은 표적 시퀀싱을 사용하여 식물과 가축의 형질을 분석하고, 환경 모니터링에서 RNA 패널은 생태계 및 산업용 생물 반응기 내 미생물 활동을 추적하는 데 도움을 주고 있습니다. 의약품 개발 파이프라인에서는 바이오마커 탐색과 동반진단약물 개발을 위해 표적 시퀀싱을 도입하는 사례가 증가하고 있습니다. 지역적으로는 임상유전체학이 보다 성숙한 북미와 서유럽에서 도입이 활발히 이루어지고 있으며, 아시아태평양에서는 연구 자금의 확대, 신흥 유전체학 생태계, 정밀의료에 대한 정부의 노력으로 인해 급속한 성장을 보이고 있습니다. 시퀀서의 휴대성이 향상되고 데이터 분석에 대한 접근성이 높아짐에 따라 학술 기관 및 진단 기관의 중소형 실험실에서도 표적화된 방법을 채택하고 있어 시장 범위와 사용 사례의 다양성이 확대되고 있습니다.

타겟 DNA RNA 시퀀싱 세계 시장 성장 가속화의 원동력은?

타겟 DNA RNA 시퀀싱 시장의 성장은 임상 수요, 연구 우선순위, 비용 효율성, 급속한 기술 성숙의 수렴에 의해 이루어지고 있습니다. 전 세계적으로 만성질환의 증가, 암 발생률, 맞춤형 의료에 대한 관심으로 인해 신속하고 실용적인 유전학적 인사이트에 대한 수요가 증가하고 있으며, 표적 시퀀싱은 이를 제공하기에 적합합니다. 전장 유전체 접근법에 비해 표적화 기법은 시퀀싱 비용이 현저히 낮고, 데이터 복잡성이 감소하며, 보고까지 걸리는 시간이 단축되어 특히 자원이 제한된 환경에서 일상적인 진단에 더 쉽게 접근할 수 있습니다. 멀티오믹스 전략의 통합과 공간 및 단일 세포 시퀀싱에 대한 관심이 높아지면서 연구자들이 높은 처리량 정확도와 데이터 관련성을 결합할 수 있는 방법을 모색함에 따라 채택이 더욱 가속화되고 있습니다. 특히 종양학, 약리유전체학, 유전질환에서 임상 사용을 위한 표적화된 NGS 패널이 규제 당국의 승인을 받으면서 이러한 접근법의 유용성이 입증되어 임상 적용이 가속화되고 있습니다. 국가 시퀀싱 프로젝트 및 바이오뱅크 개발을 위한 정부 이니셔티브와 함께 유전체학 연구에 대한 자금 조달이 증가하면서 인프라 및 지원 생태계의 폭이 넓어지고 있습니다. 학술 기관, 생명공학 기업, 진단 연구소 간의 파트너십은 특정 집단과 질병에 맞게 조정된 특수 패널의 기술 혁신과 상용화를 촉진하고 있습니다. 동시에, 사용자 친화적인 자동화된 NGS 플랫폼과 통합 분석 소프트웨어의 등장으로 중규모 및 분산형 실험실의 접근이 민주화되고 있습니다. 분자진단 및 중개 연구 분야에서 정확성, 속도, 경제성에 대한 요구가 증가함에 따라, 타겟 DNA RNA 시퀀싱은 차세대 유전체 의료를 형성하는 데 있어 점점 더 중심적인 역할을 하게 될 것입니다.

부문

제품(NGS, 기타), 워크플로우(프리 시퀀싱, 시퀀싱, 데이터), 유형(DNA 기반 타겟 시퀀싱, RNA 기반 타겟 시퀀싱), 용도(인간 바이오메디컬 연구, 식물·동물 과학, Drug Discovery, 기타), 최종 용도(학술 연구, 병원·클리닉, 제약·바이오테크놀러지 기업, 기타)

조사 대상 기업 사례

  • Agilent Technologies, Inc.
  • Azenta Life Sciences(GENEWIZ)
  • BGI Genomics
  • Bio-Rad Laboratories, Inc.
  • CD Genomics
  • Element Biosciences
  • F. Hoffmann-La Roche Ltd
  • Genomatix Software GmbH
  • GeneDx
  • HudsonAlpha Institute for Biotechnology
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Macrogen, Inc.
  • New England Biolabs
  • Novogene Corporation
  • Nugen Technologies, Inc.
  • Oxford Nanopore Technologies plc
  • Pacific Biosciences of California, Inc.
  • Paragon Genomics
  • PerkinElmer, Inc.
  • PierianDx
  • QIAGEN N.V.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.07.31

Global Targeted DNA RNA Sequencing Market to Reach US$31.4 Billion by 2030

The global market for Targeted DNA RNA Sequencing estimated at US$11.7 Billion in the year 2024, is expected to reach US$31.4 Billion by 2030, growing at a CAGR of 17.9% over the analysis period 2024-2030. NGS, one of the segments analyzed in the report, is expected to record a 15.8% CAGR and reach US$17.0 Billion by the end of the analysis period. Growth in the Other Products segment is estimated at 20.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.2 Billion While China is Forecast to Grow at 23.2% CAGR

The Targeted DNA RNA Sequencing market in the U.S. is estimated at US$3.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.9 Billion by the year 2030 trailing a CAGR of 23.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.5% and 16.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.2% CAGR.

Global Targeted DNA RNA Sequencing Market - Key Trends & Drivers Summarized

Why Is Targeted DNA RNA Sequencing Gaining Ground Over Whole Genome and Transcriptome Approaches?

In the era of precision medicine and high-throughput genomics, targeted DNA and RNA sequencing has emerged as a practical and efficient alternative to whole genome and transcriptome sequencing. By focusing on specific genomic regions or transcript subsets of interest, this method offers a highly cost-effective, scalable, and clinically relevant way to interrogate genetic variation, expression profiles, and molecular biomarkers. Unlike whole genome sequencing, which can generate enormous amounts of irrelevant data and require intensive computational resources, targeted sequencing enables researchers and clinicians to zero in on known genes, regulatory elements, or mutation hotspots linked to disease pathways. In oncology, for example, targeted sequencing panels allow clinicians to identify actionable mutations across cancer-relevant genes with faster turnaround and better interpretability. In infectious disease research, targeted RNA sequencing enables pathogen-specific transcript analysis, aiding in strain identification and drug resistance profiling. Additionally, hereditary disease diagnostics, pharmacogenomics, and immune repertoire profiling are increasingly reliant on targeted assays for precise, repeatable insights. As the healthcare and life sciences industries seek clinically actionable, time-sensitive genetic data, targeted sequencing methods are bridging the gap between research and clinical utility, offering the depth and specificity needed to answer high-impact biological questions without the burden of excessive data noise.

How Are Technology Innovations Enhancing the Efficiency and Accuracy of Targeted Sequencing?

Advancements in sequencing chemistry, probe design, amplification protocols, and bioinformatics are driving significant improvements in the sensitivity, specificity, and throughput of targeted DNA and RNA sequencing. Techniques such as hybrid capture and amplicon-based enrichment are becoming more refined, enabling accurate targeting of low-frequency variants and structurally complex genomic regions. Adaptive sampling technologies now allow for real-time target selection on nanopore sequencing platforms, reducing wasted reads and increasing efficiency. Multiplexed library preparation kits and automation-friendly workflows are cutting down turnaround times and reducing sample handling errors, while low-input and FFPE-compatible kits are expanding usability in clinical and degraded samples. On the data analysis front, integrated bioinformatics pipelines and AI-powered variant callers are enhancing the reliability of read mapping, mutation detection, and transcript quantification, even in difficult-to-sequence regions. Cloud-based platforms are facilitating collaborative research, secure data storage, and streamlined reporting for clinical labs. Furthermore, the development of dual DNA/RNA panels is supporting integrated genomic and transcriptomic profiling from a single sample, which is particularly useful in oncology and immune profiling applications. Combined with increasing read accuracy, faster sequencers, and more affordable reagent kits, these innovations are making targeted sequencing not just a focused method, but a technically sophisticated and widely deployable solution for precision diagnostics and translational research.

Where Is Targeted DNA RNA Sequencing Being Adopted, and What Are the Emerging Use Cases?

Targeted DNA and RNA sequencing is being adopted across a wide range of clinical, academic, and industrial settings, with applications extending well beyond traditional genomics research. In clinical oncology, targeted sequencing panels are now routine for solid tumors and hematologic malignancies, helping identify actionable mutations, guide therapy selection, and monitor minimal residual disease. In reproductive health and rare disease diagnostics, targeted assays enable rapid screening for pathogenic variants across defined gene sets, improving diagnostic yield while reducing costs and turnaround times. In infectious disease research, pathogen-specific RNA sequencing is being used for rapid identification of emerging variants, antimicrobial resistance markers, and transcriptional responses to therapeutic agents. The immunology and vaccine development fields are leveraging targeted T-cell and B-cell receptor sequencing to study immune repertoires and response dynamics. Beyond healthcare, agrigenomics researchers use targeted sequencing to analyze plant and livestock traits, while in environmental monitoring, RNA panels help track microbial activity in ecosystems and industrial bioreactors. Drug development pipelines are increasingly incorporating targeted sequencing for biomarker discovery and companion diagnostic development. Geographically, adoption is strong in North America and Western Europe, where clinical genomics is more mature, while Asia-Pacific is witnessing rapid growth driven by expanding research funding, genomics startup ecosystems, and government initiatives in precision medicine. With sequencing instruments becoming more portable and data analysis more accessible, small to mid-sized labs in academia and diagnostics are also embracing targeted methods, expanding market reach and diversity of use cases.

What’s Fueling the Accelerated Growth of the Global Targeted DNA RNA Sequencing Market?

The growth of the targeted DNA RNA sequencing market is being driven by the convergence of clinical demand, research prioritization, cost-efficiency, and rapid technological maturation. The global rise in chronic diseases, cancer incidence, and interest in personalized medicine is increasing demand for quick, actionable genetic insights that targeted sequencing is well-equipped to provide. Compared to whole genome approaches, targeted methods offer significantly lower sequencing costs, reduced data complexity, and faster reporting timelines-making them more accessible for routine diagnostics, especially in resource-constrained settings. The integration of multi-omic strategies and growing interest in spatial and single-cell sequencing are further fueling adoption, as researchers seek ways to combine high-throughput precision with data relevance. Regulatory approvals of targeted NGS panels for clinical use, especially in oncology, pharmacogenomics, and inherited diseases, are validating the utility of these approaches and accelerating clinical deployment. Rising funding in genomics research, coupled with government initiatives aimed at national sequencing projects and biobank development, is broadening the infrastructure and support ecosystem. Partnerships between academic institutions, biotech firms, and diagnostic labs are fostering innovation and commercialization of specialized panels tailored for specific populations or diseases. At the same time, the availability of automated, user-friendly NGS platforms and integrated analysis software is democratizing access for mid-sized and decentralized laboratories. As demand for precision, speed, and affordability grows in molecular diagnostics and translational research, targeted DNA RNA sequencing is positioned to play an increasingly central role in shaping the next generation of genomic medicine.

SCOPE OF STUDY:

The report analyzes the Targeted DNA RNA Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (NGS, Others); Workflow (Pre-sequencing, Sequencing, Data); Type (DNA-based Targeted Sequencing, RNA-based Targeted Sequencing); Application (Human Biomedical Research, Plant & Animal Sciences, Drug Discovery, Others); End-Use (Academic Research, Hospitals & Clinics, Pharma & Biotech Companies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Agilent Technologies, Inc.
  • Azenta Life Sciences (GENEWIZ)
  • BGI Genomics
  • Bio-Rad Laboratories, Inc.
  • CD Genomics
  • Element Biosciences
  • F. Hoffmann-La Roche Ltd
  • Genomatix Software GmbH
  • GeneDx
  • HudsonAlpha Institute for Biotechnology
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Macrogen, Inc.
  • New England Biolabs
  • Novogene Corporation
  • Nugen Technologies, Inc.
  • Oxford Nanopore Technologies plc
  • Pacific Biosciences of California, Inc.
  • Paragon Genomics
  • PerkinElmer, Inc.
  • PierianDx
  • QIAGEN N.V.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Targeted DNA RNA Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for Actionable Genetic Insights Throws the Spotlight on Targeted DNA RNA Sequencing in Clinical Diagnostics
    • Rising Adoption of Precision Medicine Approaches Propels Use of Focused Sequencing Panels in Oncology and Rare Disease Detection
    • Increased Interest in Transcriptomic Profiling Strengthens the Business Case for Targeted RNA Sequencing in Gene Expression Analysis
    • Integration of Sequencing into Routine Clinical Workflows Drives Adoption of Rapid and Cost-Effective Targeted Approaches
    • Advancements in Probe Design and Library Preparation Technologies Generate Higher Accuracy and Efficiency in Targeted Assays
    • Expansion of Liquid Biopsy Applications Accelerates Demand for Highly Sensitive Targeted Sequencing in Minimal Residual Disease Monitoring
    • Growing Utility in Infectious Disease and Pathogen Detection Expands the Addressable Market for Targeted Sequencing Platforms
    • Supportive Reimbursement Policies and Regulatory Approvals Spur Clinical Adoption of Targeted Genomic Tests
    • Emergence of Single-Cell and Spatial Genomics Drives Integration of Targeted Approaches in Multi-Omic Workflows
    • Use of AI and Machine Learning in Variant Calling Enhances Interpretation Accuracy and Streamlines Bioinformatics Pipelines
    • Decentralization of Genomic Testing Drives Adoption of Targeted Sequencing in Mid-Sized and Regional Laboratories
    • Rising Demand for Companion Diagnostics in Oncology and Pharmacogenomics Fuels Development of Targeted Gene Panels
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Targeted DNA RNA Sequencing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Targeted DNA RNA Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for NGS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Human Biomedical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Human Biomedical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Human Biomedical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Plant & Animal Sciences by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Plant & Animal Sciences by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Plant & Animal Sciences by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Pre-sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Pre-sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Pre-sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for DNA-based Targeted Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for DNA-based Targeted Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for DNA-based Targeted Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for RNA-based Targeted Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for RNA-based Targeted Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: World 15-Year Perspective for RNA-based Targeted Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 50: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 59: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: USA 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: USA 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • JAPAN
    • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • CHINA
    • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 95: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: China 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 101: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: China 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: China 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 107: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: China Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: China 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • EUROPE
    • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Targeted DNA RNA Sequencing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 122: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Europe Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 125: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Europe Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • FRANCE
    • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 128: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: France 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 131: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: France 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 134: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: France Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: France 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 137: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: France Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: France 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 140: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: France Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: France 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • GERMANY
    • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 146: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Germany Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 149: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Germany Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 152: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Germany Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 155: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Germany Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 158: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Italy Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 161: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Italy Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 164: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Italy Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 167: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Italy Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 170: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Italy Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 173: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: UK Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: UK 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 176: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: UK Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: UK 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 179: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: UK Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: UK 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 182: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: UK Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: UK 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 185: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UK Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: UK 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 188: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Spain Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 191: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Spain Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 194: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Spain Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 197: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Spain Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 200: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Spain Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 203: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Russia Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 206: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Russia Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 209: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Russia Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 212: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Russia Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 215: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Russia Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 218: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 221: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 224: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 233: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 234: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 236: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 239: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 251: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Australia Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 254: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Australia Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 257: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Australia Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 260: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Australia Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 263: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Australia Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • INDIA
    • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 266: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: India Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: India 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 269: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: India Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: India 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 272: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: India Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: India 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 275: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: India Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: India 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 278: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: India Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: India 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 281: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: South Korea Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 284: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: South Korea Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 287: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: South Korea Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 290: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: South Korea Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 293: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: South Korea Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 296: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 311: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 312: Latin America Historic Review for Targeted DNA RNA Sequencing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 314: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Latin America Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 317: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Latin America Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 320: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Latin America Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 323: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Latin America Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 326: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Latin America Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 329: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Argentina Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 332: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Argentina Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 335: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Argentina Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 338: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Argentina Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 341: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Argentina Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 344: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Brazil Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 347: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Brazil Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 350: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Brazil Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 353: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Brazil Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 356: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Brazil Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 359: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Mexico Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 362: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Mexico Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 365: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Mexico Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 368: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Mexico Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 371: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Mexico Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 374: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 377: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 389: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 390: Middle East Historic Review for Targeted DNA RNA Sequencing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 392: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Middle East Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 395: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Middle East Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 398: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Middle East Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 401: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Middle East Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 404: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Middle East Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 406: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 407: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Iran Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 409: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 410: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Iran Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 412: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 413: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Iran Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 415: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 416: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Iran Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 418: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 419: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Iran Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 421: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 422: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 423: Israel Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 424: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 425: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 426: Israel Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 427: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 428: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 429: Israel Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 430: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 431: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 432: Israel Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 433: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 434: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 435: Israel Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 436: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 437: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 438: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 439: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 440: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 441: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 442: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 443: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 444: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 445: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 446: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 447: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 448: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 450: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 451: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 452: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 453: UAE Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 454: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 455: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 456: UAE Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 457: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 458: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 459: UAE Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 460: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 461: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 462: UAE Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 463: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 464: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 465: UAE Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 466: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 467: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 468: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 469: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 470: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 471: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 472: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 473: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 474: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 475: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 476: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 477: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 478: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 480: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 481: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
  • AFRICA
    • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 482: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 483: Africa Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 484: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
    • TABLE 485: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 486: Africa Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 487: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
    • TABLE 488: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 489: Africa Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 490: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 491: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 492: Africa Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 493: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
    • TABLE 494: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 495: Africa Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 496: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제